Get the Stockscreener App
9.77
7.96%
0.72
After Hours:
9.77
Addex Therapeutics Ltd Adr stock is traded at $9.77, with a volume of 13,822.
It is up +7.96% in the last 24 hours and down -10.04% over the past month.
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
See More
Previous Close:
$9.05
Open:
$9.98
24h Volume:
13,822
Relative Volume:
0.05
Market Cap:
$10.44M
Revenue:
$2.23M
Net Income/Loss:
$-12.33M
P/E Ratio:
-7.32
EPS:
-1.3347
Net Cash Flow:
$-11.75M
1W Performance:
-7.83%
1M Performance:
-10.04%
6M Performance:
-23.67%
1Y Performance:
+2,442%
1-Day Range:
$9.50
$10.00
1-Week Range:
$8.92
$10.66
52-Week Range:
$0.325
$27.90
Addex Therapeutics Ltd Adr Stock (ADXN) Company Profile
Name
Addex Therapeutics Ltd Adr
Sector
Industry
Phone
-
Address
-
Addex Therapeutics Ltd Adr Stock (ADXN) Latest News
Earnings call: Addex Therapeutics reports half-year financials and R&D updates - Investing.com
Earnings call: Addex Therapeutics reports half-year financials and R&D updates - Investing.com India
ADMA Biologics stock soars to all-time high of $19.36 - Investing.com
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest? - Zacks Investment Research
ADMA Biologics (NASDAQ:ADMA) Reaches New 52-Week High at $19.42 - MarketBeat
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year? - Yahoo Finance
Addex Stock Soars on Crucial Update From Indivior Research Deal - Zacks Investment Research
Addex Stock Soars on Crucial Update From Indivior Research Deal - Yahoo Finance
Addex Stock Soars on Crucial Update From Indivior Research Deal - Nasdaq
ADXN Stock on the Rise: A Promising Investment - The InvestChronicle
There Are Mixed Signals on the Chart for Addex Therapeutics Ltd ADR (ADXN) - US Post News
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Nasdaq
Is Alcon (ALC) Outperforming Other Medical Stocks This Year? - Yahoo Canada Finance
Addex’s Partner Discontinues ADX71149 development in Epilepsy - GlobeNewswire Inc.
Addex Therapeutics presents results from GABAB PAM cough program - TipRanks
Addex Presents Positive Results from GABAB PAM Cough - GlobeNewswire Inc.
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS) - GlobeNewswire Inc.
Addex Shareholders Approve All Resolutions at Annual General Meeting - GlobeNewswire Inc.
Addex to Participate at the Benchmark Company Healthcare House Call Conference - The Globe and Mail
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Canada Shine On
Earnings call: Addex Therapeutics reports on Q1 2024 with mixed results - Investing.com India
Earnings call: Addex Therapeutics reports on Q1 2024 with mixed results By Investing.com - Investing.com
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Addex Convenes Annual General Meeting 2024 - GlobeNewswire Inc.
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024 - GlobeNewswire Inc.
Genocea (GNCA) Begins Phase I/IIa Study for Solid Tumor Drug - Yahoo Movies UK
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Movies UK
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Canada Shine On
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Moves to Buy: Rationale Behind the Upgrade - Yahoo Canada Shine On
Addex to Present at Bio€quity Europe 2024 - GlobeNewswire Inc.
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Movies Canada
Why Philips Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket - Benzinga
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study - GlobeNewswire Inc.
Addex to Present at the Swiss Biotech Day 2024 - GlobeNewswire Inc.
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Benzinga
Why Macatawa Bank Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket - Benzinga
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024 - GlobeNewswire Inc.
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket - Benzinga
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Benzinga
Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders - GlobeNewswire Inc.
Addex Therapeutics Receives Nasdaq Approval for ADS Ratio Change By Investing.com - Investing.com India
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo New Zealand News
Addex Therapeutics ADR (NASDAQ: ADXN) Has Moved an M4 PAMS Program to Optimization - BP Journal
Addex Therapeutics (ADXN) Sees Hammer Chart Pattern: Time to Buy? - Yahoo Movies UK
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer I - Benzinga
ASLAN Pharma (NASDAQ:ASLN) Stock Quotes, Forecast and News Summary - Benzinga
Addex Therapeutics Ltd Adr Stock (ADXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):